Welcome to our dedicated page for Perrigo Co Plc news (Ticker: PRGO), a resource for investors and traders seeking the latest updates and insights on Perrigo Co Plc stock.
Perrigo Company plc (NYSE: PRGO) is a pure-play self-care and consumer health company whose news flow is closely tied to its over-the-counter (OTC) product portfolio, category performance and strategic initiatives. The company regularly issues updates on its Consumer Self-Care Americas and Consumer Self-Care International segments, highlighting trends in categories such as Upper Respiratory, Pain & Sleep Aids, Digestive Health, Nutrition, Vitamins, Minerals and Supplements, Women’s Health, Skin Care, Oral Care and Healthy Lifestyle.
On this page, readers can follow Perrigo’s earnings announcements, where the company discusses net sales, organic growth, segment performance and the impact of divestitures and exited products. These releases often reference store brand market share gains in OTC categories, performance of key brands and progress under its Three-S plan (Stabilize, Streamline, Strengthen). Updates on Project Energize, the global investment and efficiency program designed to support the One Perrigo growth strategy, are also a recurring theme in recent communications.
Perrigo’s news also covers portfolio actions and strategic reviews. The company has disclosed an agreement to sell its Dermacosmetics branded business in certain European markets and has announced strategic reviews of its Oral Care and infant formula businesses. In addition, readers will find announcements related to dividends, participation in investor conferences and brand-level initiatives, such as collaborations involving Opill®, which Perrigo describes as the first daily birth control pill available without a prescription in the United States.
Investors, analysts and consumers can use this news feed to monitor how Perrigo is positioning its OTC and self-care portfolio, how its store brand and branded businesses are performing across regions and categories, and how management is adjusting the company’s structure and investments in response to market conditions.
Perrigo Company plc (NYSE; TASE: PRGO) announced its voluntary delisting from the Tel Aviv Stock Exchange (TASE) on November 22, 2021, following the divestiture of its Israeli-based operations. The delisting is expected to take effect three months post-request, with shares transitioning to the New York Stock Exchange (NYSE). CEO Murray S. Kessler highlighted this decision as part of Perrigo's significant transformation over the past three years. The company remains committed to its self-care strategy, being a major player in over-the-counter health products.
Perrigo Company plc (NYSE: PRGO) reported its third quarter fiscal 2021 results, revealing net sales of $1.04 billion, a 4.0% increase year-over-year. Organic growth was 2.6% despite challenges including a 5.7 percentage point hit from supply chain disruptions. Adjusted diluted EPS decreased 25.0% to $0.45. The company sees potential in the rebound of its cough/cold business and anticipates adjusted diluted EPS of $2.00 to $2.10 for 2021. Key developments include the completion of the RX business divestiture and acquisition of HRA Pharma.
Perrigo Company plc (NYSE: PRGO) announced that Rolf A. Classon will not seek re-election as Chairman at the annual meeting in May 2022. Orlando D. Ashford, who joined the board in December 2020, is expected to succeed him. Classon, who has served as Chairman since 2018, expressed optimism for Perrigo's future during his tenure, which has seen a transformation into a consumer self-care company. CEO Murray Kessler praised Classon's leadership, while emphasizing Ashford's relevant experience as a benefit for the company moving forward.
Perrigo Company plc (NYSE: PRGO) has declared a quarterly dividend of $0.24 per share, scheduled for payment on December 21, 2021, to shareholders recorded as of December 3, 2021. The company continues to reinforce its position as a leading provider of quality self-care products, appealing to a growing market for affordable health solutions. The dividend announcement highlights Perrigo's ongoing commitment to returning value to its shareholders while maintaining a focus on consumer self-care.
Perrigo Company plc (NYSE; TASE: PRGO) will announce its third quarter 2021 financial results on November 10, 2021, at 8:30 A.M. (EST). A conference call will follow, available via webcast on the company’s investor relations site. Perrigo is a leading provider of self-care products and OTC health solutions, holding a significant market position with over 9,000 SKUs in the U.S. and ranking among the top 10 OTC companies in Europe.
Perrigo Company plc (NYSE: PRGO) has appointed Jim Dillard as the new EVP and President of Consumer Self-Care Americas (CSCA), effective immediately. Dillard, previously EVP and Chief Scientific Officer, will continue reporting to CEO Murray Kessler. The company has completed its transformation to focus on consumer self-care and resolved an Irish tax uncertainty. Kessler emphasized the importance of profitable growth, while Dillard expressed enthusiasm for leveraging innovation and improving margins. Rich Sorota has mutually separated from the company.
Perrigo Company has settled a significant tax dispute with the Irish Revenue Commissioners regarding an amended income tax assessment. Initially claiming €1.6 billion, the tax liability was reduced to €297 million, which the company will pay, resulting in a net payment of €266.1 million after tax credits. This settlement eliminates a major source of uncertainty for Perrigo, allowing it to refocus on its consumer self-care strategy. Additionally, Perrigo received €355 million related to a previous arbitration award, bolstering its financial position.
Perrigo Company has announced a binding offer to acquire Héra SAS for €1.8 billion (approximately $2.1 billion) in cash. This acquisition aims to enhance Perrigo's position as a global leader in consumer self-care, expanding its portfolio with HRA's leading OTC brands including Compeed®, ellaOne®, and Mederma®. The deal is expected to generate substantial value, achieving mid-teen net sales growth and significant operational synergies, projected to save over €30 million annually by 2023. The transaction is set to close by the end of H1 2022, subject to regulatory approvals.
Perrigo Company plc (NYSE: PRGO) announced that its President and CEO, Murray S. Kessler, along with CFO Ray Silcock, will participate in investor meetings at the Barclays Global Consumer Staples Conference on September 9, 2021. No formal presentation will be made. As a leader in providing affordable self-care products, Perrigo is the top store brand OTC player in the U.S. and ranks among the top 10 OTC companies in Europe. The company's focus on consumer health solutions positions it well within the competitive landscape.
Perrigo Company plc (NYSE: PRGO) reported a 3.4% increase in net sales for Q2 2021, totaling $981 million, driven by growth across most businesses, despite a weak cough/cold season. However, adjusted diluted EPS fell 15.3% to $0.50 due to higher input costs and reinstated marketing expenditures. The company reaffirmed its 2021 sales guidance, anticipating organic growth of 3%, although EPS expectations were adjusted to the lower end of $2.50 to $2.70 as inflationary pressures persist. Despite challenges, management expresses optimism for future sales recovery and growth opportunities.